The translational relevance of the immunomodulatory activities of DHAs in cancer is sustained by the results from our previous studies, in a syngeneic mouse tumor model, demonstrating how guadecitabine or DAC were able to sensitize tumor cells to the anti-tumor activity of CTLA-4 blockade, inducing a significantly stronger tumor growth reduction compared to treatment with single agents (Covre et al., 2015a,b). Here, CTLA4 is linked to neoplasm.